The prognostic outcome of ‘type 2 diabetes mellitus and breast cancer’ association pivots on hypoxia-hyperglycemia axis

[1]  A. Bhatti,et al.  Regulatory MicroRNAs in T2DM and Breast Cancer , 2021, Processes.

[2]  T. George,et al.  New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review , 2020, Cancer medicine.

[3]  B. Szmyd,et al.  HIF-1α as a Mediator of Insulin Resistance, T2DM, and Its Complications: Potential Links With Obstructive Sleep Apnea , 2020, Frontiers in Physiology.

[4]  C. Diorio,et al.  The Importance of Breast Adipose Tissue in Breast Cancer , 2020, International journal of molecular sciences.

[5]  Qian Ning,et al.  Metformin suppresses HIF‐1α expression in cancer‐associated fibroblasts to prevent tumor‐stromal cross talk in breast cancer , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Ehinger,et al.  Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer , 2019, PloS one.

[7]  V. Moreno-Manzano,et al.  Mechanism and Consequences of The Impaired Hif-1α Response to Hypoxia in Human Proximal Tubular HK-2 Cells Exposed to High Glucose , 2019, Scientific Reports.

[8]  T. Kietzmann,et al.  DUBs, Hypoxia, and Cancer. , 2019, Trends in cancer.

[9]  M. Bhat,et al.  Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality , 2019, Cancers.

[10]  C. Wiggins,et al.  Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[11]  V. Sánchez-Margalet,et al.  Obesity and Breast Cancer: Role of Leptin , 2019, Front. Oncol..

[12]  N. Pace,et al.  Metformin as an adjuvant in breast cancer treatment , 2019, SAGE open medicine.

[13]  B. Cho,et al.  Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors , 2019, Cancer Chemotherapy and Pharmacology.

[14]  Yuhua Song,et al.  The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity , 2019, Cancer management and research.

[15]  H. Zare.  Effects of Salvia Officinalis Extract on the Breast Cancer Cell Line , 2019, SciMedicine Journal.

[16]  N. Forsyth,et al.  Hypoxia-Modified Cancer Cell Metabolism , 2019, Front. Cell Dev. Biol..

[17]  H. Harada,et al.  HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance , 2019, International journal of molecular sciences.

[18]  Xingli Wu,et al.  The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis , 2019, Therapeutic advances in medical oncology.

[19]  A. Jeyasekharan,et al.  ROS and the DNA damage response in cancer , 2018, Redox biology.

[20]  Ayesha Obaid,et al.  Model-based in silico analysis of the PI3K/Akt pathway: the elucidation of cross-talk between diabetes and breast cancer , 2018, PeerJ.

[21]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[22]  L. Yao,et al.  PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia , 2018, Molecular medicine reports.

[23]  Guihua Liu,et al.  The PI3K/AKT pathway in obesity and type 2 diabetes , 2018, International journal of biological sciences.

[24]  J. Ma,et al.  Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF-1α pathway , 2018, International journal of oncology.

[25]  S. McGee,et al.  Metabolic reprogramming in type 2 diabetes and the development of breast cancer. , 2018, The Journal of endocrinology.

[26]  R. Ceredig,et al.  The Transcription Factor Hif-1 Enhances the Radio-Resistance of Mouse MSCs , 2018, Front. Physiol..

[27]  L. Keinan-Boker,et al.  Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Joshua M. Stuart,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[29]  Chiun-Sheng Huang,et al.  Association between radiosensitivity and molecular subtypes in patients with early-stage breast cancer and lymph node-negative status , 2017 .

[30]  J. Palmer,et al.  Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. , 2017, Cancer research.

[31]  K. McGlynn,et al.  Diabetes and Overall Survival among Breast Cancer Patients in the U.S. Military Health System , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[32]  P. Giorgi Rossi,et al.  Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy , 2017, BMC Cancer.

[33]  C. Hudis,et al.  Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells – a novel mechanism for the obesity-breast cancer link , 2017, International Journal of Obesity.

[34]  S. Subbiah,et al.  Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. , 2017, Indian journal of cancer.

[35]  C. Drevon,et al.  Hypoxia in Combination With Muscle Contraction Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle via the HIF-1α Pathway , 2017, Diabetes.

[36]  C. Peiró,et al.  IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus , 2017, Front. Pharmacol..

[37]  J. Holly,et al.  Hypoxia negates hyperglycaemia-induced chemo-resistance in breast cancer cells: the role of insulin-like growth factor binding protein 2 , 2017, Oncotarget.

[38]  A. Ghasemi,et al.  Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate , 2017, Oxidative medicine and cellular longevity.

[39]  R. Ling,et al.  Activation of hypoxia-inducible factor-1α by prolonged in vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells. , 2017, Biochemical and biophysical research communications.

[40]  S. Russell,et al.  Type 1 Diabetes - A Clinical Perspective. , 2017, Point of care.

[41]  Y. Hwangbo,et al.  Acute Hyperglycemia Associated with Anti-Cancer Medication , 2017, Endocrinology and metabolism.

[42]  V. Sukhatme,et al.  Low‐Dose Farnesyltransferase Inhibitor Suppresses HIF‐1α and Snail Expression in Triple‐Negative Breast Cancer MDA‐MB‐231 Cells In Vitro , 2017, Journal of cellular physiology.

[43]  G. Ren,et al.  Diabetes mellitus and prognosis in women with breast cancer , 2016, Medicine.

[44]  D. Leroith,et al.  Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Y. Shah,et al.  Hypoxia-inducible factors: a central link between inflammation and cancer. , 2016, The Journal of clinical investigation.

[46]  M. Bolanowski,et al.  Diabetes and Cancer: a Review of Current Knowledge. , 2016, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[47]  Gretchen A. Stevens,et al.  Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants , 2016, Lancet.

[48]  S. Giordano,et al.  Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. , 2016, JAMA oncology.

[49]  K. Balamurugan.  HIF‐1 at the crossroads of hypoxia, inflammation, and cancer , 2016, International journal of cancer.

[50]  J. M. García-Martínez,et al.  From obesity to diabetes and cancer: epidemiological links and role of therapies , 2016, British Journal of Cancer.

[51]  M. Kohno,et al.  Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. , 2016, American journal of physiology. Endocrinology and metabolism.

[52]  J. Bussink,et al.  Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies , 2016, Future science OA.

[53]  T. García-Caballero,et al.  Ki-67 is a prognostic marker for hormone receptor positive tumors , 2016, Clinical and Translational Oncology.

[54]  A. Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[55]  D. Morisky,et al.  Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. , 2015, Diabetes research and clinical practice.

[56]  Peijun Liu,et al.  Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis , 2015, Oncotarget.

[57]  Zhonghu Bai,et al.  Breast cancer intrinsic subtype classification, clinical use and future trends. , 2015, American journal of cancer research.

[58]  R. Molinari,et al.  Effect of Dietary ω-3 Polyunsaturated Fatty Acid DHA on Glycolytic Enzymes and Warburg Phenotypes in Cancer , 2015, BioMed research international.

[59]  H. Mukhtar,et al.  Resveratrol nanoformulation for cancer prevention and therapy , 2015, Annals of the New York Academy of Sciences.

[60]  Robert R. Henry,et al.  Type 2 diabetes mellitus , 2015, Nature Reviews Disease Primers.

[61]  B. Calys-Tagoe,et al.  A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana , 2015, BMC Clinical Pathology.

[62]  Nidhi Parashar,et al.  Prevalence of molecular subtypes of invasive breast cancer: A retrospective study. , 2015, Medical journal, Armed Forces India.

[63]  F. Guadagni,et al.  Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress , 2015, Oxidative medicine and cellular longevity.

[64]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[65]  V. Moreno,et al.  Association of diabetes and diabetes treatment with incidence of breast cancer , 2015, Acta Diabetologica.

[66]  N. Turner,et al.  Diabetes and Its Link with Cancer: Providing the Fuel and Spark to Launch an Aggressive Growth Regime , 2015, BioMed research international.

[67]  S. Wootton,et al.  Obesity in breast cancer--what is the risk factor? , 2015, European journal of cancer.

[68]  D. Noonan,et al.  The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells , 2015, International journal of cancer.

[69]  M. Danova,et al.  Diabetes and cancer: A critical appraisal of the pathogenetic and therapeutic links. , 2015, Biomedical reports.

[70]  G. Baldwin,et al.  HIF1α expression under normoxia in prostate cancer--which pathways to target? , 2015, The Journal of urology.

[71]  Hui Liu,et al.  [Expression of HIF-1α and correlation with angiogenesis in tissue of breast cancer complicated with diabetes]. , 2015, Zhonghua yi xue za zhi.

[72]  K. Collins.  The Diabetes-Cancer Link , 2014, Diabetes Spectrum.

[73]  P. Scherer,et al.  Hyperglycemia as a Risk Factor for Cancer Progression , 2014, Diabetes & metabolism journal.

[74]  L. Pfeffer,et al.  MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers , 2014, Breast Cancer Research.

[75]  Jihan Wang,et al.  Altered Expression of Hypoxia-Inducible Factor-1α (HIF-1α) and Its Regulatory Genes in Gastric Cancer Tissues , 2014, PloS one.

[76]  Jung-whan Kim,et al.  Increased Adipocyte O2 Consumption Triggers HIF-1α, Causing Inflammation and Insulin Resistance in Obesity , 2014, Cell.

[77]  M. Blagosklonny,et al.  Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium , 2014, Cell Death and Disease.

[78]  G. Ren,et al.  On the status of β-cell dysfunction and insulin resistance of breast cancer patient without history of diabetes after systemic treatment , 2014, Medical Oncology.

[79]  H. Sakaue,et al.  Deletion of Hypoxia-Inducible Factor-1α in Adipocytes Enhances Glucagon-Like Peptide-1 Secretion and Reduces Adipose Tissue Inflammation , 2014, PloS one.

[80]  B. Vergès,et al.  Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. , 2014, European journal of endocrinology.

[81]  J. M. García-Martínez,et al.  A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose. , 2013, Journal of molecular endocrinology.

[82]  K. Alberti,et al.  Diagnosis and Classification of Diabetes Mellitus , 2013, Diabetes Care.

[83]  M. Blagosklonny.  TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists , 2013, Cell Death and Disease.

[84]  G. Semenza,et al.  Role of hypoxia-inducible factors in breast cancer metastasis. , 2013, Future oncology.

[85]  A. Ferrara,et al.  Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes , 2013, Diabetes Care.

[86]  Guoxing Wang,et al.  The Possible Mechanisms Underlying the Impairment of HIF-1α Pathway Signaling in Hyperglycemia and the Beneficial Effects of Certain Therapies , 2013, International journal of medical sciences.

[87]  S. Kempa,et al.  The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond , 2013, Oncogene.

[88]  D. Leroith,et al.  Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer , 2013, Diabetes Care.

[89]  G. Mills,et al.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.

[90]  M. Reginato,et al.  The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance* , 2013, The Journal of Biological Chemistry.

[91]  S. Marcella,et al.  Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus , 2013, Diabetes, obesity & metabolism.

[92]  Geoff M. Anderson,et al.  Incidence of diabetes among postmenopausal breast cancer survivors , 2013, Diabetologia.

[93]  Gunnar Cedersund,et al.  Insulin Signaling in Type 2 Diabetes , 2013, The Journal of Biological Chemistry.

[94]  S. Habib,et al.  Diabetes and Risk of Cancer , 2013, ISRN oncology.

[95]  D. Rose,et al.  The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. , 2012, Endocrine-related cancer.

[96]  J. Valderas,et al.  Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare , 2012, BMC Cancer.

[97]  G. Eslick,et al.  Diabetes increases the risk of breast cancer: a meta-analysis. , 2012, Endocrine-related cancer.

[98]  N. Parsa,et al.  Environmental Factors Inducing Human Cancers , 2012, Iranian journal of public health.

[99]  M. Trautmann,et al.  Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. , 2012, Clinical therapeutics.

[100]  M Smans,et al.  Diabetes and breast cancer risk: a meta-analysis , 2012, British Journal of Cancer.

[101]  S. Gapstur,et al.  Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults , 2012, Diabetes Care.

[102]  M. White,et al.  Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 , 2012, Diabetologia.

[103]  Xu-hui Zhang,et al.  Increased risk of cancer in patients with type 2 diabetes mellitus: A retrospective cohort study in China , 2012, BMC Public Health.

[104]  J. Manson,et al.  Diabetes, metformin, and breast cancer in postmenopausal women. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  C. Tseng,et al.  The Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the Taiwanese , 2012, Experimental diabetes research.

[106]  A. Munkarah,et al.  Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis , 2012, Journal of oncology.

[107]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[108]  A. Neugut,et al.  The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project , 2012, Cancer Causes & Control.

[109]  M. Lai,et al.  Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[110]  M. Dehghani,et al.  Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer , 2012, Hormones and Cancer.

[111]  Qiwen Ben,et al.  Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies , 2012, International journal of cancer.

[112]  M. L. Bruin,et al.  Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data , 2012, Diabetologia.

[113]  J. Pouysségur,et al.  Glucose-Induced O2 Consumption Activates Hypoxia Inducible Factors 1 and 2 in Rat Insulin-Secreting Pancreatic Beta-Cells , 2012, PloS one.

[114]  C. Mantzoros,et al.  Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. , 2011, Metabolism: clinical and experimental.

[115]  Ying Jiang,et al.  Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies , 2011, European Journal of Epidemiology.

[116]  O. Gavrilova,et al.  Disruption of Hypoxia-Inducible Factor 1 in Adipocytes Improves Insulin Sensitivity and Decreases Adiposity in High-Fat Diet–Fed Mice , 2011, Diabetes.

[117]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[118]  M. Lux,et al.  Diabetes and prognosis in a breast cancer cohort , 2011, Journal of Cancer Research and Clinical Oncology.

[119]  P. Pereira,et al.  Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes , 2011, Diabetologia.

[120]  V. Patil,et al.  E-Cadherin as a diagnostic biomarker in breast cancer , 2011, North American journal of medical sciences.

[121]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[122]  H. Idikio,et al.  Human Cancer Classification: A Systems Biology- Based Model Integrating Morphology, Cancer Stem Cells, Proteomics, and Genomics , 2011, Journal of Cancer.

[123]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[124]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[125]  D. Yee,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[126]  V. Haase.  The sweet side of HIF. , 2010, Kidney international.

[127]  Y. Makino,et al.  High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. , 2010, Kidney international.

[128]  N. Probst-Hensch,et al.  IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity , 2010, Clinical Cancer Research.

[129]  Laura Sciacca,et al.  Diabetes and cancer. , 2009, Endocrine-related cancer.

[130]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[131]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[132]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[133]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[134]  M. Hebrok,et al.  A Role for von Hippel-Lindau Protein in Pancreatic β-Cell Function , 2009, Diabetes.

[135]  L. Pirola,et al.  Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. , 2009, Biochimica et biophysica acta.

[136]  I. Ben-Sahra,et al.  Hypoxia Decreases Insulin Signaling Pathways in Adipocytes , 2009, Diabetes.

[137]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[138]  G. Semenza,et al.  Age‐dependent impairment of HIF‐1α expression in diabetic mice: Correction with electroporation‐facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells , 2008, Journal of cellular physiology.

[139]  S. Leung,et al.  Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer , 2008, Clinical Cancer Research.

[140]  T. Franke,et al.  PI3K/Akt: getting it right matters , 2008, Oncogene.

[141]  A. Russo,et al.  Insulin-dependent leptin expression in breast cancer cells. , 2008, Cancer research.

[142]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[143]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[144]  D. Balzi,et al.  Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[145]  S. Sohail,et al.  Breast cancer in pakistan - awareness and early detection. , 2007, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[146]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[147]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[148]  C. Mantzoros,et al.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.

[149]  J. Schölmerich,et al.  Mechanisms of Disease: adipokines and breast cancer—endocrine and paracrine mechanisms that connect adiposity and breast cancer , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[150]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.

[151]  Arvind Kumar Srivastava,et al.  Diabetes mellitus: complications and therapeutics. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[152]  N. Jeandidier,et al.  Hyperglycémie et pathologies aiguës , 2006 .

[153]  J. Isaacs,et al.  BRCA1 Plays a Role in the Hypoxic Response by Regulating HIF-1α Stability and by Modulating Vascular Endothelial Growth Factor Expression* , 2006, Journal of Biological Chemistry.

[154]  E. Surmacz,et al.  Leptin and cancer , 2006, Journal of cellular physiology.

[155]  C. Mantzoros,et al.  Adiponectin and cancer: a systematic review , 2006, British Journal of Cancer.

[156]  A. Russo,et al.  Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli , 2006, Clinical Cancer Research.

[157]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[158]  J. Coebergh,et al.  Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. , 2005, European journal of cancer.

[159]  S. Bao,et al.  The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.

[160]  L. Poellinger,et al.  Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. , 2004, Diabetes.

[161]  J. Nyengaard,et al.  Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. , 2004, Diabetes.

[162]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[163]  D. Lawlor,et al.  Hyperinsulinaemia and Increased Risk of Breast Cancer: Findings From the British Women's Heart and Health Study , 2004, Cancer Causes & Control.

[164]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[165]  N. Sang,et al.  MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300* , 2003, The Journal of Biological Chemistry.

[166]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[167]  R. Marfella,et al.  Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1 , 2002, Diabetologia.

[168]  R. Wenger,et al.  Normoxic induction of the hypoxia‐inducible factor 1α by insulin and interleukin‐1β involves the phosphatidylinositol 3‐kinase pathway , 2002 .

[169]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.

[170]  Alexander S. Banks,et al.  Activation of Downstream Signals by the Long Form of the Leptin Receptor* , 2000, The Journal of Biological Chemistry.

[171]  D. Mottet,et al.  ERK activation upon hypoxia: involvement in HIF‐1 activation , 2000, FEBS letters.

[172]  C. Mantzoros,et al.  Serum Steroid Hormone Levels, Sex Hormone‐Binding Globulin, and Body Mass Index in the Etiology of Postmenopausal Breast Cancer , 1996, Epidemiology.

[173]  L. Boros,et al.  Reversal of enhanced pancreatic cancer growth in diabetes by insulin. , 1995, Surgery.

[174]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[175]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[176]  T. Agner,et al.  Androgens and estrogens in postmenopausal insulin-treated diabetic women. , 1989, The Journal of clinical endocrinology and metabolism.

[177]  R. Cafaro.  Hypoxia: Its Causes and Symptoms. , 1960, Journal of the American Dental Society of Anesthesiology.

[178]  F. Couch,et al.  Genomic Biomarkers for Breast Cancer Risk. , 2016, Advances in experimental medicine and biology.

[179]  M. Faheem,et al.  Type 2 Diabetes Mellitus as a Risk Factor for Female Breast Cancer in the Population of Northern Pakistan. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[180]  Z. Werb,et al.  The Role of Stroma in Tumor Development. , 2015, Cancer journal.

[181]  Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015 .

[182]  C. Kahn,et al.  Insulin receptor signaling in normal and insulin-resistant states. , 2014, Cold Spring Harbor perspectives in biology.

[183]  Antonio Avallone,et al.  New perspective for an old antidiabetic drug: metformin as anticancer agent. , 2014, Cancer treatment and research.

[184]  D. Leroith,et al.  The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. , 2013, Vitamins and hormones.

[185]  G. Umpierrez,et al.  Patient guide to managing hyperglycemia (high blood sugar) in the hospital. , 2012, The Journal of clinical endocrinology and metabolism.

[186]  Harman Ece,et al.  Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels? , 2012, Asian Pacific journal of cancer prevention : APJCP.

[187]  Nagy Ma.  HIF-1 is the Commander of Gateways to Cancer , 2011 .

[188]  Honglian Shi,et al.  HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells , 2011, Cellular and Molecular Life Sciences.

[189]  R. Baumgartner,et al.  Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  M. Simon,et al.  Hypoxia-inducible factors as essential regulators of inflammation. , 2010, Current topics in microbiology and immunology.

[191]  Shuiqing Zeng 曾水清,et al.  Up-regulation of HIF-1α and VEGF expression by elevated glucose concentration and hypoxia in cultured human retinal pigment epithelial cells , 2006, Journal of Huazhong University of Science and Technology.

[192]  N. Jeandidier,et al.  [Hyperglycemia and acute illness]. , 2006, Annales d'endocrinologie.

[193]  Shuiqing Zeng,et al.  Up-regulation of HIF-1α and VEGF expression by elevated glucose concentration and hypoxia in cultured human retinal pigment epithelial cells , 2006, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[194]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[195]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[196]  R. Wenger,et al.  Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. , 2002, FEBS letters.

[197]  Arbeit Jm.  Quiescent Hypervascularity Mediated by Gain of HIF-1α Function , 2002 .

[198]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  E. Giovannucci.  American Institute for Cancer Research 11th Annual Research Conference on Diet, Nutrition and Cancer Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence , 2001 .

[200]  H. Grosse.  [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.